Author Correction: Casdatifan shows durable response linked to HIF-2α biology in kidney cancer
Toni K. Choueiri, Jaime Merchán, Amita Patnaik, Alexandra Drakaki et autres
us, kr (code pays fourni par la source)
0 citations
Nature
Brian I. Rini
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
1330Publications signalées
79464Citations signalées
3Affiliations récentes
Les institutions déclarées
Les domaines associés
Renal cell carcinoma treatmentRenal and related cancersCancer Genomics and DiagnosticsCancer Immunotherapy and BiomarkersBladder and Urothelial Cancer Treatments
Les publications récentes
Casdatifan shows durable response linked to HIF-2α biology in kidney cancer
Toni K. Choueiri, Jamie Merchan, Amita Patnaik, Alexandra Drakaki et autres
us, kr (code pays fourni par la source)
0 citations
Nature
Not All Predictors Of RCC Clusters Are The Same: An individual sample predictive model to classify patients with metastatic renal cell carcinoma
Anupama Reddy, W. Jared Brewer, Scott M. Haake, Brian I. Rini
us (code pays fourni par la source)
0 citations
bioRxiv (Cold Spring Harbor Laboratory)
Podcast on the emerging role of PD-(L)1/VEGF bispecific antibodies in the evolving advanced renal cell carcinoma treatment landscape
Adis Journals on behalf of:, Brian I. Rini, Benjamin Garmezy
0 citations
Figshare
Podcast on the emerging role of PD-(L)1/VEGF bispecific antibodies in the evolving advanced renal cell carcinoma treatment landscape
Adis Journals on behalf of:, Brian I. Rini, Benjamin Garmezy
0 citations
Figshare
Comprehensive Genomic and Transcriptomic Characterization of Matched Primary and Recurrent Tumors in High-risk Localized Renal Cell Carcinoma
Wenxin Xu, Brian I. Rini, Laurence Albigès, Xiaobin Tang et autres
us, fr, gb, es (code pays fourni par la source)
2 citations
European Urology
Abstract A034: HIF-2-mediated gene expression is highest in metastatic and cluster-exclude clear cell renal cell carcinoma tumors
Scott M. Haake, Katy Beckermann, Alex Nesta, Eric Davis et autres
us (code pays fourni par la source)
0 citations
Cancer Research
Artificial intelligence (AI) as a practical decision support tool for oncologists: Genitourinary (GU) cancer cases.
Mohammad Jahanzeb, Kayla Haines, Erin Shonkwiler, Musa Kiyani et autres
us (code pays fourni par la source)
1 citation
Journal of Clinical Oncology
Phase 1b/2 KEYMAKER-U03 substudy 03C of belzutifan plus zanzalintinib or belzutifan monotherapy for recurrent clear cell renal cell carcinoma during or after anti–PD-(L)1 therapy.
R Motzer, Laurence Albigès, Cristina Suárez, Thomas Powles et autres
us, fr, es, gb, il (code pays fourni par la source)
0 citations
Journal of Clinical Oncology
A randomized phase 2 trial of nivolumab, relatlimab plus ipilimumab vs. nivolumab plus ipilimumab in first-line advanced renal cell carcinoma.
Eric Jonasch, Nizar M. Tannir, Andrew W. Hahn, Sangeeta Goswami et autres
us (code pays fourni par la source)
0 citations
Journal of Clinical Oncology
Activity and biomarker analyses with casdatifan (cas), a next-generation HIF-2α inhibitor, in refractory clear cell renal cell carcinoma (ccRCC): Results from ARC-20.
Toni K. Choueiri, Jaime R. Merchan, A. Patnaik, A. Drakaki et autres
us, kr (code pays fourni par la source)
2 citations
Journal of Clinical Oncology
Pathologic findings and clinical outcomes after immune checkpoint blockade in renal cell carcinoma patients undergoing deferred consolidative nephrectomy.
Paulo Siqueira Amaral, Rohit Mehra, Jennifer Gordetsky, T. Zhang et autres
us (code pays fourni par la source)
0 citations
Journal of Clinical Oncology
BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.